Kharfan-Dabaja MA et al. |
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. |
2017 |
Bone Marrow Transplant. |
pmid:27819684
|
Jacobson P et al. |
Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. |
2001 |
Bone Marrow Transplant. |
pmid:11781626
|
Menillo SA et al. |
Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. |
2001 |
Bone Marrow Transplant. |
pmid:11781637
|
Steg RE et al. |
Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. |
1999 |
Bone Marrow Transplant. |
pmid:10338054
|
Mori T et al. |
Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. |
2009 |
Bone Marrow Transplant. |
pmid:19270729
|
Misawa A et al. |
FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation. |
2000 |
Bone Marrow Transplant. |
pmid:10673708
|
Kanda Y et al. |
A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. |
2016 |
Bone Marrow Transplant. |
pmid:26437063
|
Ratanatharathorn V et al. |
Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. |
2015 |
Bone Marrow Transplant. |
pmid:25285804
|
Kato H et al. |
Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. |
2014 |
Bone Marrow Transplant. |
pmid:24317130
|
Takamatsu Y et al. |
Intravenous cyclosporine and tacrolimus caused anaphylaxis but oral cyclosporine capsules were tolerated in an allogeneic bone marrow transplant recipient. |
2001 |
Bone Marrow Transplant. |
pmid:11571519
|
Oshima K et al. |
Target blood concentrations of CYA and tacrolimus in randomized controlled trials for the prevention of acute GVHD after hematopoietic SCT. |
2010 |
Bone Marrow Transplant. |
pmid:19701249
|
Furlong T et al. |
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. |
2000 |
Bone Marrow Transplant. |
pmid:11100278
|
Ikegame K et al. |
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. |
2003 |
Bone Marrow Transplant. |
pmid:12796797
|
Jabbour E et al. |
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. |
2007 |
Bone Marrow Transplant. |
pmid:17603511
|
Ram R et al. |
Prophylaxis regimens for GVHD: systematic review and meta-analysis. |
2009 |
Bone Marrow Transplant. |
pmid:18997826
|
Neuman DL et al. |
Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease. |
2005 |
Bone Marrow Transplant. |
pmid:16151424
|
Messina C et al. |
Prevention and treatment of acute GvHD. |
2008 |
Bone Marrow Transplant. |
pmid:18545247
|
Yoshida Y et al. |
FK506-associated limbic injury following umbilical cord blood transplantation. |
2003 |
Bone Marrow Transplant. |
pmid:12942100
|
Eagle DA et al. |
Gastroparesis following bone marrow transplantation. |
2001 |
Bone Marrow Transplant. |
pmid:11498745
|
Jacobson P et al. |
Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. |
1998 |
Bone Marrow Transplant. |
pmid:9720734
|
Hsiao CC et al. |
Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. |
2002 |
Bone Marrow Transplant. |
pmid:12476284
|
Yu C et al. |
Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. |
1996 |
Bone Marrow Transplant. |
pmid:8722370
|
Elefante A et al. |
Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. |
2006 |
Bone Marrow Transplant. |
pmid:16518428
|
Mawardi H et al. |
Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. |
2010 |
Bone Marrow Transplant. |
pmid:19881552
|
Kanda J et al. |
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. |
2013 |
Bone Marrow Transplant. |
pmid:23334274
|
Al-Kadhimi Z et al. |
Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. |
2017 |
Bone Marrow Transplant. |
pmid:28581472
|
Boughton O et al. |
A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. |
2013 |
Br J Clin Pharmacol |
pmid:23305195
|
Antignac M et al. |
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. |
2007 |
Br J Clin Pharmacol |
pmid:17425625
|
Nishimoto M et al. |
Drug interactions and safety profiles with concomitant use of caspofungin and calcineurin inhibitors in allogeneic haematopoietic cell transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28407449
|
Böttiger Y et al. |
Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. |
1999 |
Br J Clin Pharmacol |
pmid:10510159
|
Cusinato DA et al. |
Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. |
2014 |
Br J Clin Pharmacol |
pmid:24528196
|
Mai I et al. |
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. |
2004 |
Br J Clin Pharmacol |
pmid:15521904
|
Woillard JB et al. |
Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. |
2010 |
Br J Clin Pharmacol |
pmid:20565459
|
Tang JT et al. |
The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. |
2017 |
Br J Clin Pharmacol |
pmid:27753146
|
Hawwa AF et al. |
Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. |
2009 |
Br J Clin Pharmacol |
pmid:19740399
|
Zahir H et al. |
Factors affecting variability in distribution of tacrolimus in liver transplant recipients. |
2004 |
Br J Clin Pharmacol |
pmid:14998426
|
Atcheson BA et al. |
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. |
2005 |
Br J Clin Pharmacol |
pmid:15752372
|
Jalil MH et al. |
Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. |
2014 |
Br J Clin Pharmacol |
pmid:23738951
|
Johnston A and Holt DW |
Therapeutic drug monitoring of immunosuppressant drugs. |
1999 |
Br J Clin Pharmacol |
pmid:10233195
|
Billaud EM et al. |
Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. |
1998 |
Br J Clin Pharmacol |
pmid:9764970
|
Horigome A et al. |
Lymphocyte-sensitivity to glucocorticoid correlates with the sensitivity to cyclosporin A and tacrolimus in chronic renal failure patients. |
1999 |
Br J Clin Pharmacol |
pmid:10583028
|
Øzbay LA et al. |
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. |
2012 |
Br J Clin Pharmacol |
pmid:21988494
|
Størset E et al. |
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. |
2017 |
Br J Clin Pharmacol |
pmid:28374426
|
Jacobo-Cabral CO et al. |
Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. |
2015 |
Br J Clin Pharmacol |
pmid:25846845
|
Størset E et al. |
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. |
2014 |
Br J Clin Pharmacol |
pmid:25279405
|
Suzuki Y et al. |
Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. |
2008 |
Br J Clin Pharmacol |
pmid:18341670
|
Pham VV et al. |
Graft rejection: pharmacogenetic analysis or drug anamnesis? |
2008 |
Br J Clin Pharmacol |
pmid:18341681
|
Gonschior AK et al. |
Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). |
1994 |
Br J Clin Pharmacol |
pmid:7534100
|
Zhao CY et al. |
External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. |
2016 |
Br J Clin Pharmacol |
pmid:26574188
|
Barraclough KA et al. |
Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. |
2011 |
Br J Clin Pharmacol |
pmid:21219401
|
Cremers S et al. |
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. |
2005 |
Br J Clin Pharmacol |
pmid:16120063
|
Barau C et al. |
Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. |
2012 |
Br J Clin Pharmacol |
pmid:22329639
|
Choi JH et al. |
Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. |
2007 |
Br J Clin Pharmacol |
pmid:17391324
|
Musuamba FT et al. |
Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. |
2013 |
Br J Clin Pharmacol |
pmid:23072565
|
Vanhove T et al. |
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
2016 |
Br J Clin Pharmacol |
pmid:27501475
|
Woillard JB et al. |
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. |
2011 |
Br J Clin Pharmacol |
pmid:21284698
|
Staatz CE et al. |
Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose. |
2015 |
Br J Clin Pharmacol |
pmid:26235203
|
Vanhove T et al. |
Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'. |
2015 |
Br J Clin Pharmacol |
pmid:26235051
|
Vanhove T et al. |
Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. |
2017 |
Br J Clin Pharmacol |
pmid:28168728
|
Størset E et al. |
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28146606
|
Mück W et al. |
Tacrolimus/cerivastatin interaction study in liver transplant recipients. |
2001 |
Br J Clin Pharmacol |
pmid:11488782
|
Kassir N et al. |
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. |
2014 |
Br J Clin Pharmacol |
pmid:24977292
|
Passey C et al. |
Dosing equation for tacrolimus using genetic variants and clinical factors. |
2011 |
Br J Clin Pharmacol |
pmid:21671989
|
Zheng S et al. |
Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. |
2013 |
Br J Clin Pharmacol |
pmid:23528073
|
Satoh S et al. |
Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. |
2008 |
Br J Clin Pharmacol |
pmid:18429967
|
de Jonge H et al. |
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. |
2015 |
Br J Clin Pharmacol |
pmid:26114223
|
Xin HW et al. |
Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. |
2007 |
Br J Clin Pharmacol |
pmid:17506780
|
Mathew BS et al. |
A limited sampling strategy for tacrolimus in renal transplant patients. |
2008 |
Br J Clin Pharmacol |
pmid:18662286
|
Christians U et al. |
Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. |
1996 |
Br J Clin Pharmacol |
pmid:8866917
|
Sam WJ et al. |
Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. |
2000 |
Br J Clin Pharmacol |
pmid:11136292
|
Calvo PL et al. |
Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28044353
|
Stifft F et al. |
Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. |
2014 |
Br J Clin Pharmacol |
pmid:24809233
|
Størset E et al. |
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance. |
2017 |
Br J Clin Pharmacol |
pmid:28008657
|
Renders L et al. |
Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. |
2003 |
Br J Clin Pharmacol |
pmid:12895195
|
Knops N et al. |
Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation. |
2017 |
Br J Clin Pharmacol |
pmid:27966227
|
Elens L et al. |
The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. |
2013 |
Br J Clin Pharmacol |
pmid:23163400
|
Bremer S et al. |
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28686294
|
Elens L et al. |
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. |
2014 |
Br J Clin Pharmacol |
pmid:24118098
|
Hesselink DA et al. |
Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. |
2003 |
Br J Clin Pharmacol |
pmid:12919182
|
Vanhove T et al. |
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28603840
|
James DG |
Which immunomodulator? |
1991 |
Br J Clin Pract |
pmid:1718384
|
Bowman H and Lennard TW |
Immunosuppressive drugs. |
1992 Nov 4-17 |
Br J Hosp Med |
pmid:1282440
|
Shahid S et al. |
Chronic hepatitis in the transplant patient. |
2017 |
Br J Hosp Med (Lond) |
pmid:28692371
|
Murphy CC et al. |
Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. |
2007 |
Br J Ophthalmol |
pmid:16973657
|
Oh-i K et al. |
Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. |
2007 |
Br J Ophthalmol |
pmid:16987901
|
Tam PM et al. |
Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis--case series. |
2010 |
Br J Ophthalmol |
pmid:20558422
|
Young AL et al. |
Allo-limbal transplantation in patients with limbal stem cell deficiency. |
1999 |
Br J Ophthalmol |
pmid:10574823
|
Rao SK et al. |
Limbal allografting using FK-506. |
1999 |
Br J Ophthalmol |
pmid:10574824
|
Oh-i K et al. |
Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). |
2007 |
Br J Ophthalmol |
pmid:17940132
|
Fukushima A et al. |
Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. |
2014 |
Br J Ophthalmol |
pmid:24695688
|
Joseph A et al. |
Tacrolimus immunosuppression in high-risk corneal grafts. |
2007 |
Br J Ophthalmol |
pmid:16956911
|
Hogan A et al. |
Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. |
2005 |
Br J Ophthalmol |
pmid:16113360
|
Lake DB and Poole TR |
Tacrolimus. |
2003 |
Br J Ophthalmol |
pmid:12488279
|
Magalhaes OA et al. |
Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. |
2013 |
Br J Ophthalmol |
pmid:24008822
|
Shoughy SS and Tabbara KF |
Topical tacrolimus solution in autoimmune polyglandular syndrome-1-associated keratitis. |
2017 |
Br J Ophthalmol |
pmid:28137823
|
Leder HA et al. |
Disappearance of classic birdshot spots after immunosuppression with tacrolimus and mycophenolate mofetil. |
2008 |
Br J Ophthalmol |
pmid:18227210
|
Aoki S et al. |
Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. |
2005 |
Br J Ophthalmol |
pmid:15665364
|
Ortega KL et al. |
Oral ulcers after a transplant. |
2010 |
Br J Oral Maxillofac Surg |
pmid:19231045
|
Cetinkale O et al. |
The use of FK506 and skin allografting for the treatment of severe burns in an animal model. |
1993 |
Br J Plast Surg |
pmid:7690295
|
Anoopkumar-Dukie S et al. |
Mitochondrial modulation of oxygen-dependent radiosensitivity in some human tumour cell lines. |
2009 |
Br J Radiol |
pmid:19366737
|